Clinical Scorecard: Industry Insights: Genomic Testing for Early-Stage Breast Cancer

At a Glance

Key Highlights

• Genomic assays redefine adjuvant decision-making, identifying patients who benefit from chemotherapy.
• The MINDACT trial shows genomic low-risk HR+/HER2- patients do not benefit from adjuvant chemotherapy.
• Genomic profiling predicts response to neoadjuvant therapy and informs surgical planning.
• NCCN guidelines now recognize genomic testing for neoadjuvant decision-making.
• Genomic insights help balance treatment intensity with quality-of-life considerations.

Guideline-Based Recommendations

Diagnosis

• Use histopathologic assessment alongside genomic testing for comprehensive tumor evaluation.

Management

• Personalize treatment regimens based on genomic profiling results.

Monitoring & Follow-up

• Regularly assess treatment response and adjust based on genomic insights.

Risks

• Identify patients at high risk for recurrence to avoid overtreatment and unnecessary toxicities.

Patient & Prescribing Data

HR+/HER2- early-stage breast cancer patients

Genomic tests can determine the necessity of anthracycline-based chemotherapy and extended endocrine therapy.

Clinical Best Practices

• Incorporate genomic testing into treatment planning for HR+/HER2- breast cancer.
• Utilize genomic insights to guide surgical decisions and timing.
• Engage in discussions with patients about the implications of genomic results on treatment options.

Related Resources & Content

• NCCN Clinical Practice Guidelines
• FLEX Study (NCT03053193)
• MINDACT Trial